Conference
A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma
Authors
Cheung MC; Mittmann N; Shepherd L; Risebrough N; Imrie KR; Hay AE; Djurfeldt M; Meyer RM; Chen BE; Crump M
Volume
49
Pagination
pp. S326-S326
Publisher
ELSEVIER SCI LTD
Publication Date
September 1, 2013
Name of conference
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO
Conference place
Amsterdam, NETHERLANDS
Conference start date
September 27, 2013
Conference end date
October 1, 2013
Conference proceedings
EUROPEAN JOURNAL OF CANCER
ISSN
0959-8049